BerGenBio reports Phase Ib/II data for bemcentinib in melanoma

BerGenBio ASA (OSE:BGBIO) reported data from 19 patients with metastatic melanoma in a Phase Ib/II trial evaluating bemcentinib (BGB324) plus PD-1 inhibitor Keytruda pembrolizumab from

Read the full 252 word article

User Sign In